Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest News

Four presentations from Nerviano Medical Sciences at the 2015 AACR meeting Nerviano, Italy, March 18th – Nerviano Medical Sciences will present four posters, one selected for an oral presentation, at the American Association for Cancer Research (AACR) Annual Meeting 2015, April 18 - 22, 2015, Pennsylvania Convention Center, Philadelphia, Pennsylvania. Read more
Tiziana Life Sciences licenses milciclib from Nerviano Medical Sciences London, 20 January 2015 – Tiziana Life Sciences plc (“Tiziana”, “the Company”, AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, is pleased to announce that it has exclusively licensed milciclib from Nerviano Medical Sciences Group (“Nerviano”), an Italian company dedicated to the discovery and development of... Read more
NMS GROUP: dati di bilancio 2013 e pre closing 2014 Vendita di molecole con incassi upfront per un totale di oltre 52 milioni di euro (erano zero nel 2008). Il Gruppo raggiunge il pareggio nel ‘13 e va in Utile Netto positivo nel 2014 (rispetto a una perdita di 79 mio nel ‘08). Nell'ultimo biennio l'indebitamento è stato ridotto di 21 milioni di euro. Il patrimonio netto migliora anche per effetto della riduzione dei costi operativi (-36%) e... Read more
Series of B-Raf inhibitors discovered by Nerviano Medical Sciences published on ChemMedChem Nerviano, Italy, December 11, 2014. Nerviano Medical Sciences researchers report the identification and optimization of one B-RAF inhibitor belonging to the chemical class of diarylthiazoles on the journal ChemMedChem (“Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect”.... Read more
Cellectis e Accelera siglano un accordo per il completamento degli studi preclinici di UCART19 di Cellectis, una nuova e promettente terapia per per leucemie e linfomi Milano (Italia) e Parigi (Francia), 9 giugno 2014 – Cellectis (Alternext: ALCLS), società leader nel campo delle terapie cellulari basate su linfociti T allogenici ingegnerizzati con recettori chimerici antigene-specifici (CAR), e Accelera, società del Gruppo Nerviano Medical Sciences che svolge servizi di Ricerca a contratto (CRO) e che collabora con aziende farmaceutiche e biotecnologiche a... Read more
Il Prof. Carlo Croce, Vice Presidente con delega alla direzione scientifica di Nerviano, ambasciatore della ricerca italiana sul cancro al Quirinale al cospetto del Presidente della Repubblica Milano, 6 novembre 2014 – È toccato al Prof. Carlo Croce, Vice Presidente con delega alla direzione scientifica del Centro Ricerche di Nerviano (MI) e Direttore dell'Istituto di Genetica presso il Comprehensive Cancer Center dell’Ohio State University, il prestigioso ruolo di ambasciatore della ricerca italiana in ambito oncologico nel mondo al cospetto del Presidente della Repubblica Giorgio... Read more
Nerviano Medical Sciences discloses novel molecules suitable for the generation of antibody drug conjugates at the World ADC, San Diego (USA) 2014 Nerviano, November 6, 2014 - Nerviano Medical Sciences disclosed data on novel molecules suitable for the generation of antibody drug conjugates at the meeting World ADC San Diego (USA), 26-29 October 2014. Antibody drug conjugates (ADCs) represent a valuable approach to cancer therapy whereby antibodies are combined with potent cytotoxic compounds for selective tumor cell delivery and... Read more
Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014           Nerviano, Italy – October 28, 2014 – Nerviano Medical Sciences announces that results from a single-arm Phase II study of Milciclib in patients with thymic carcinoma and thymoma were disclosed in a poster discussion session at the XVI Congresso Nazionale AIOM, October 24-26, 2014, Rome, Italy. This clinical trial represents collaborative work of Nerviano... Read more
   
Publications  
007  
   

Nerviano Medical Sciences

Nerviano Medical SciencesHeart of the innovative Group focused on the identification of new therapeutic strategies, research and development of new drugs, shapes the future of the oncology.

Read more...

Accelera

AcceleraAn Italian preclinical research Company, recognized and certified, all over the world provides high standard integrated services, with reliability and international compliance.

Read more...

CLIOSS

CliossWith an extensive experience, Clioss partners worldwide Biopharma, Biotech and Research Institutions for full cycle drug development from First-Time-In-Man.

Read more...

NerPharMa

NerpharmaConsolidated know-how, the highest quality standards characterize the offered services: for the formulation, the recording and production of the active principle.

Read more...